Rucker, James

Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study

Carhart-Harris, R. L., Bolstridge, M., Rucker, J., Day, C. M. J., Erritzoe, D., Kaelen, M., Bloomfield, M., Rickard, J. A., Forbes, B., Feilding, A., et al. (2016) · The Lancet Psychiatry

Psychedelics and Drug StudiesTreatment of Major Depression

Cited by 1,540

Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression

Goodwin, G. M., Aaronson, S. T., Alvarez, O., Arden, P. C., Baker, A., Bennett, J. C., Bird, C., Blom, R. E., Brennan, C., Brusch, D., et al. (2022) · New England Journal of Medicine

Psychedelics and Drug StudiesTreatment of Major Depression

Cited by 1,167

Psilocybin with psychological support for treatment-resistant depression: six-month follow-up

Carhart-Harris, R. L., Bolstridge, M., Day, C. M. J., Rucker, J., Watts, R., Erritzoe, D. E., Kaelen, M., Giribaldi, B., Bloomfield, M., Pilling, S., et al. (2018) · Psychopharmacology

Psychedelics and Drug StudiesTreatment of Major Depression

Cited by 970

Psychiatry & the psychedelic drugs. Past, present & future

Rucker, J. J. H., Iliff, J., & Nutt, D. J. (2018) · Neuropharmacology

Psychedelics and Drug StudiesForensic Toxicology and Drug Analysis

Cited by 343

Psychedelics, mystical experience, and therapeutic efficacy: a systematic review

Ko, K., Knight, G., Rucker, J. J., & Cleare, A. J. (2022) · Frontiers in Psychiatry

Psychedelics and Drug StudiesReligion, Spirituality, and Psychology

Cited by 306

Male-biased autosomal effect of 16p13.11 copy number variation in neurodevelopmental disorders

Tropeano, M., Ahn, J. W., Dobson, R. J. B., Breen, G., Rucker, J., Dixit, A., Pal, D. K., McGuffin, P., Farmer, A., White, P. S., et al. (2013) · PLoS ONE

Genomic variations and chromosomal abnormalitiesGenetics and Neurodevelopmental Disorders

Cited by 154

Psychedelic therapy for depressive symptoms: A systematic review and meta-analysis

Ko, K., Kopra, E. I., Cleare, A. J., & Rucker, J. J. (2023) · Journal of Affective Disorders

Psychedelics and Drug StudiesTreatment of Major Depression

Cited by 150

International online survey of 1048 individuals with functional neurological disorder

Butler, M., Shipston‐Sharman, O., Seynaeve, M., Bao, J., Pick, S., Bradley‐Westguard, A., Ilola, E., Mildon, B., Golder, D., Rucker, J., et al. (2021) · European Journal of Neurology

Psychosomatic Disorders and Their TreatmentsFibromyalgia and Chronic Fatigue Syndrome Research

Cited by 119

Expectancy in placebo-controlled trials of psychedelics: if so, so what?

Butler, M., Jelen, L., & Rucker, J. (2022) · Psychopharmacology

Psychedelics and Drug StudiesPain Management and Placebo Effect

Cited by 100

Association of Copy Number Variation of the 15q11.2 BP1-BP2 Region With Cortical and Subcortical Morphology and Cognition

Writing Committee for the ENIGMA-CNV Working Group, van der Meer, D., Sønderby, I. E., Kaufmann, T., Walters, G. B., Abdellaoui, A., Ames, D., Amunts, K., Andersson, M., Armstrong, N. J., et al. (2020) · JAMA Psychiatry

Genomic variations and chromosomal abnormalitiesGenetics and Neurodevelopmental Disorders

Cited by 87

Effects of copy number variations on brain structure and risk for psychiatric illness: Large‐scale studies from the ENIGMA working groups on CNVs

Sønderby, I. E., Ching, C. R. K., Thomopoulos, S. I., van der Meer, D., Sun, D., Villalon‐Reina, J. E., Agartz, I., Amunts, K., Arango, C., Armstrong, N. J., et al. (2022) · Human Brain Mapping

Genomic variations and chromosomal abnormalitiesGenetic Associations and Epidemiology

Cited by 67

Dose response of the 16p11.2 distal copy number variant on intracranial volume and basal ganglia

Sønderby, I. E., Gústafsson, Ó., Doan, N. T., Hibar, D. P., Martin-Brevet, S., Abdellaoui, A., Ames, D., Amunts, K., Andersson, M., Armstrong, N. J., et al. (2020) · Molecular Psychiatry

Genomic variations and chromosomal abnormalitiesGenetics and Neurodevelopmental Disorders

Cited by 66

Genome-wide association analysis of copy number variation in recurrent depressive disorder

Rucker, J. J. H., Breen, G., Pinto, D., Pedroso, I., Lewis, C. M., Cohen-Woods, S., Uher, R., Schosser, A., Rivera, M., Aitchison, K. J., et al. (2013) · Molecular Psychiatry

Genomic variations and chromosomal abnormalitiesGenetic Associations and Epidemiology

Cited by 51

Historic psychedelic drug trials and the treatment of anxiety disorders.

Weston, N. M., Gibbs, D., Bird, C. I. V., Daniel, A., Jelen, L. A., Knight, G., Goldsmith, D., Young, A. H., & Rucker, J. J. (2020) · Depression and Anxiety

Psychedelics and Drug StudiesPsychotherapy Techniques and Applications

Cited by 38

Clinical and cost-effectiveness of lithium versus quetiapine augmentation for treatment-resistant depression: a pragmatic, open-label, parallel-group, randomised controlled superiority trial in the UK

Cleare, A. J., Kerr-Gaffney, J., Goldsmith, K., Zenasni, Z., Yaziji, N., Jin, H., Colasanti, A., Geddes, J. R., Kessler, D., McAllister-Williams, R. H., et al. (2025) · The Lancet Psychiatry

Treatment of Major DepressionBipolar Disorder and Treatment

Cited by 18